227 related articles for article (PubMed ID: 34994334)
1. L-asparaginase-mediated Therapy in L-asparagine Auxotrophic Cancers: A Review.
Sindhu R; Manonmani HK
Anticancer Agents Med Chem; 2022; 22(13):2393-2410. PubMed ID: 34994334
[TBL] [Abstract][Full Text] [Related]
2.
Van Trimpont M; Schalk AM; De Visser Y; Nguyen HA; Reunes L; Vandemeulebroecke K; Peeters E; Su Y; Lee H; Lorenzi PL; Chan WK; Mondelaers V; De Moerloose B; Lammens T; Goossens S; Van Vlierberghe P; Lavie A
Haematologica; 2023 Feb; 108(2):409-419. PubMed ID: 35979719
[TBL] [Abstract][Full Text] [Related]
3. Asparaginase in the treatment of non-ALL hematologic malignancies.
Emadi A; Zokaee H; Sausville EA
Cancer Chemother Pharmacol; 2014 May; 73(5):875-83. PubMed ID: 24515335
[TBL] [Abstract][Full Text] [Related]
4. Design and Characterization of Erwinia Chrysanthemi l-Asparaginase Variants with Diminished l-Glutaminase Activity.
Nguyen HA; Su Y; Lavie A
J Biol Chem; 2016 Aug; 291(34):17664-76. PubMed ID: 27354283
[TBL] [Abstract][Full Text] [Related]
5. Bacterial l-asparaginases for cancer therapy: Current knowledge and future perspectives.
Ghasemian A; Al-Marzoqi AH; Al-Abodi HR; Alghanimi YK; Kadhum SA; Shokouhi Mostafavi SK; Fattahi A
J Cell Physiol; 2019 Nov; 234(11):19271-19279. PubMed ID: 30993718
[TBL] [Abstract][Full Text] [Related]
6. A Novel l-Asparaginase with low l-Glutaminase Coactivity Is Highly Efficacious against Both T- and B-cell Acute Lymphoblastic Leukemias
Nguyen HA; Su Y; Zhang JY; Antanasijevic A; Caffrey M; Schalk AM; Liu L; Rondelli D; Oh A; Mahmud DL; Bosland MC; Kajdacsy-Balla A; Peirs S; Lammens T; Mondelaers V; De Moerloose B; Goossens S; Schlicht MJ; Kabirov KK; Lyubimov AV; Merrill BJ; Saunthararajah Y; Van Vlierberghe P; Lavie A
Cancer Res; 2018 Mar; 78(6):1549-1560. PubMed ID: 29343523
[TBL] [Abstract][Full Text] [Related]
7. Use of L-asparaginase in childhood ALL.
Müller HJ; Boos J
Crit Rev Oncol Hematol; 1998 Aug; 28(2):97-113. PubMed ID: 9768345
[TBL] [Abstract][Full Text] [Related]
8. L-Asparaginase delivery systems targeted to minimize its side-effects.
Talluri VP; Mutaliyeva B; Sharipova A; Ulaganathan V; Lanka SS; Aidarova S; Suigenbayeva A; Tleuova A
Adv Colloid Interface Sci; 2023 Jun; 316():102915. PubMed ID: 37159987
[TBL] [Abstract][Full Text] [Related]
9. Glutaminase activity determines cytotoxicity of L-asparaginases on most leukemia cell lines.
Parmentier JH; Maggi M; Tarasco E; Scotti C; Avramis VI; Mittelman SD
Leuk Res; 2015 Jul; 39(7):757-62. PubMed ID: 25941002
[TBL] [Abstract][Full Text] [Related]
10. L-asparaginase anti-tumor activity in pancreatic cancer is dependent on its glutaminase activity and resistance is mediated by glutamine synthetase.
Blachier J; Cleret A; Guerin N; Gil C; Fanjat JM; Tavernier F; Vidault L; Gallix F; Rama N; Rossignol R; Piedrahita D; Andrivon A; Châlons-Cottavoz M; Aguera K; Gay F; Horand F; Laperrousaz B
Exp Cell Res; 2023 May; 426(2):113568. PubMed ID: 36967104
[TBL] [Abstract][Full Text] [Related]
11. Microbial L-asparaginase as a promising enzyme for treatment of various cancers.
Darvishi F; Jahanafrooz Z; Mokhtarzadeh A
Appl Microbiol Biotechnol; 2022 Sep; 106(17):5335-5347. PubMed ID: 35871694
[TBL] [Abstract][Full Text] [Related]
12. In silico engineering of L-asparaginase to have reduced glutaminase side activity for effective treatment of acute lymphoblastic leukemia.
Ln R; Doble M; Rekha VP; Pulicherla KK
J Pediatr Hematol Oncol; 2011 Dec; 33(8):617-21. PubMed ID: 22042278
[TBL] [Abstract][Full Text] [Related]
13. Microbes Producing L-Asparaginase free of Glutaminase and Urease isolated from Extreme Locations of Antarctic Soil and Moss.
Ashok A; Doriya K; Rao JV; Qureshi A; Tiwari AK; Kumar DS
Sci Rep; 2019 Feb; 9(1):1423. PubMed ID: 30723240
[TBL] [Abstract][Full Text] [Related]
14. The glutaminase activity of L-asparaginase is not required for anticancer activity against ASNS-negative cells.
Chan WK; Lorenzi PL; Anishkin A; Purwaha P; Rogers DM; Sukharev S; Rempe SB; Weinstein JN
Blood; 2014 Jun; 123(23):3596-606. PubMed ID: 24659632
[TBL] [Abstract][Full Text] [Related]
15. Crystal structure of active site mutant of antileukemic L-asparaginase reveals conserved zinc-binding site.
Borek D; Kozak M; Pei J; Jaskolski M
FEBS J; 2014 Sep; 281(18):4097-111. PubMed ID: 25040257
[TBL] [Abstract][Full Text] [Related]
16. Enzyme-induced asparagine and glutamine depletion and immune system function.
Kafkewitz D; Bendich A
Am J Clin Nutr; 1983 Jun; 37(6):1025-30. PubMed ID: 6342356
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetic/pharmacodynamic relationships of asparaginase formulations: the past, the present and recommendations for the future.
Avramis VI; Panosyan EH
Clin Pharmacokinet; 2005; 44(4):367-93. PubMed ID: 15828851
[TBL] [Abstract][Full Text] [Related]
18. Rational engineering and insight for a L-glutaminase activity reduced type II L-asparaginase from Bacillus licheniformis and its antileukemic activity in vitro.
Zhou Y; Shen J; Chi H; Zhu X; Lu Z; Lu F; Zhu P
Int J Biol Macromol; 2024 Feb; 257(Pt 2):128690. PubMed ID: 38092107
[TBL] [Abstract][Full Text] [Related]
19. L-glutaminase and L-asparaginase by extracorporeal route in acute lymphoblastic leukemia therapy.
Giordano C; Esposito R; Mazzola G; Vecchio G; Pluvio M; Cirillo D; Capasso GB; Buonanno G
Int J Artif Organs; 1981 Sep; 4(5):244-8. PubMed ID: 6947966
[TBL] [Abstract][Full Text] [Related]
20. What makes a good new therapeutic L-asparaginase?
Beckett A; Gervais D
World J Microbiol Biotechnol; 2019 Sep; 35(10):152. PubMed ID: 31552479
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
